Today: 30 April 2026
MediaTek stock price drops 3.4% as Taiwan market shuts; what investors watch next week
8 February 2026
2 mins read

MediaTek stock price drops 3.4% as Taiwan market shuts; what investors watch next week

Taipei, Feb 8, 2026, 08:36 (GMT+8) — The market is shut.

  • MediaTek shares ended Friday in the red, shaping expectations for the coming week.
  • The chip designer is pushing further into data-center chips, shifting its sights past smartphones.
  • The January sales update lands right next to the Lunar New Year break on the calendar.

MediaTek Inc slid 3.4% to finish at NT$1,710 on Friday. Shares ranged from NT$1,690 up to NT$1,755 during the session, while volume hit roughly 11.8 million. Taiwan’s market will not open over the weekend.

Investors are staring at two narratives as next week approaches: on one hand, the data-center boom is still powering ahead; on the other, tech stocks are looking less steady. This month’s extended Lunar New Year break is squeezing the window for new developments even tighter.

Here’s the thing: MediaTek relies a lot on chips for phones and other consumer electronics. If demand slips, it tends to hit monthly sales and margins right away.

MediaTek told reporters in Taipei on Friday it’s set to double down on data-center tech, targeting areas like advanced packaging—techniques that combine several chips into a single unit—and fast interconnects. President Joe Chen pointed to a clear pivot toward high-performance computing, noting the company is now producing ASICs, or application-specific chips, for cloud operators. Chen added that MediaTek is teaming up with Taiwan Semiconductor Manufacturing Co on co-packaged optics, which uses optical links within chip packages. The company is also lining up a 400-gigabit-per-second SerDes data interface for release later this year.

Earlier this week, chief executive Rick Tsai flagged that AI-fueled demand is driving up costs through the semiconductor supply chain. MediaTek, Tsai said, plans to tweak pricing and manage supply with profitability in mind. “We will also adjust our pricings to reflect the rising supply chain costs,” Tsai said. Reuters

MediaTek’s fourth-quarter numbers are in: net sales reached NT$150.2 billion, according to its latest report. Net income landed at NT$23.1 billion, earnings per share at NT$14.39. Compared with the same quarter last year, sales were up 8.8%, while net income slipped 3.6%.

The stock lost ground as investors pulled back from Asian tech following a solid rally. “What we’re seeing now feels more like investors de-risking and locking in gains,” eToro market analyst Zavier Wong said. Reuters

The smartphone supply chain is facing another headache: higher memory prices are causing fresh bottlenecks. Counterpoint Research forecasts a 7% drop in global shipments of advanced smartphone chips for 2026, citing these rising costs. Multiple major brokerages now see the supply squeeze dragging on into 2027.

The data-center shift isn’t without headaches. Cloud giants tend to order in unpredictable bursts, and advanced packaging is still a bottleneck—delays or tighter margins could hit right as outlays climb.

The next key event looms: MediaTek’s investor calendar points to a January sales update landing on Feb. 10, just ahead of the Lunar New Year break. According to TAIFEX, Feb. 11 marks the last session before the Chinese New Year holiday hits, with trading set to resume Feb. 23—raising the stakes for any numbers out before the market pause.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Zhongji Innolight stock slides nearly 4% into China’s Monday open — what traders watch next
Previous Story

Zhongji Innolight stock slides nearly 4% into China’s Monday open — what traders watch next

Renesas stock price jumps again as $3 billion SiTime deal keeps traders hooked on 6723
Next Story

Renesas stock price jumps again as $3 billion SiTime deal keeps traders hooked on 6723

Go toTop